Navigation Links
China-Biotics, Inc. Appoints New Chief Financial Officer
Date:3/6/2009

SHANGHAI, March 6 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced Lewis Fan will succeed Raymond Li as Chief Financial Officer, effective March 6, 2009. Mr. Li will continue to serve as Vice President of Finance to the Company.

Reporting to Mr. Jinan Song, Chairman and Chief Executive Officer, Mr. Fan will be responsible for all aspects of China-Biotics' finance functions, including accounting, financial planning, tax, treasury and audit. Prior to joining China-Biotics, Mr. Fan was Vice President and Senior Equity Analyst for Brean Murray, Carret & Co., where he covered the Chinese healthcare industry. He previously served as an equity analyst at UBS and as an emerging markets strategist at Deutsche Bank.

"I want to thank Raymond for his dedicated contributions as our Chief Financial Officer. He steered this company through its first public financing and has been chiefly responsible for our transition last year to the Nasdaq Global Market. We look forward to his continuing input and experience," said Mr. Song. "We are also excited to welcome Lewis as our new CFO. His combined technical knowledge in both finance and science will be an ideal fit as we move into the next phase of our life as a public company."

Prior to his Wall Street career, Mr. Fan served as a research scientist focusing on natural product drug discovery at Schering-Plough. He holds a Master of Business Administration degree in finance from New York University, a Master of Science degree in medicinal chemistry from the University of Michigan and a Bachelor of Arts degree with honors in biology and chemistry from Luther College.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

     CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
2. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
3. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
4. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
5. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
6. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
7. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
8. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
9. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. China-Biotics, Inc. Files Application for Nasdaq Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... ANGELES , Feb. 16, 2017   ... ), a clinical-stage biotechnology company developing first-in-class biological ... announced that it has elected to terminate its ... natriuretic peptide receptor agonists, including Cenderitide. ... strategic move as we prioritize our efforts to ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
(Date:2/16/2017)... , Feb. 16, 2017  Rhythm, ... rare genetic deficiencies that result in life-threatening ... a $41 million mezzanine round of financing ... OrbiMed, MPM Capital, New Enterprise Associates, Pfizer ... undisclosed public healthcare investment fund. Rhythm will ...
(Date:2/15/2017)... ... 15, 2017 , ... Park Systems , a leader in Atomic Force ... that drastically boosts productivity with single click reliable nanoscale images, is now available on ... up and taking the image once done manually by the operator producing high quality ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):